 | • レポートコード：MRC2301A007 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、248ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に217.67百万ドルであった世界のキャッスルマン病治療市場規模が、2022年に249.01百万ドルに到達し、2027年まで年平均14.57%で成長して492.42百万ドルまで拡大すると予測しています。本レポートは、キャッスルマン病治療の世界市場について総合的・多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患型別（多中心性キャッスルマン病、単中心性キャッスルマン病）分析、適応疾患別（巨大良性リンパ腫、巨大リンパ節過形成、リンパ節過誤腫、血管腫性リンパ、その他）分析、治療方法別（抗ウイルス治療薬、化学治療、コルチコステロイド、免疫治療、その他）分析、用途別（外来手術センター、感染症）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。本資料には、AbbVie Inc.、Amgen Inc.、Bayer AG、Boehringer Ingelheim GmbH、Bristol-Myers Squibb、EUSA Pharma, Inc.、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、GlaxoSmithKline PLCなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のキャッスルマン病治療市場規模：疾患型別 - 多中心性キャッスルマン病治療の市場規模 - 単中心性キャッスルマン病治療の市場規模 ・世界のキャッスルマン病治療市場規模：適応疾患別 - 巨大良性リンパ腫における市場規模 - 巨大リンパ節過形成における市場規模 - リンパ節過誤腫における市場規模 - 血管腫性リンパにおける市場規模 - その他における市場規模 ・世界のキャッスルマン病治療市場規模：治療方法別 - 抗ウイルス治療薬における市場規模 - 化学治療における市場規模 - コルチコステロイドにおける市場規模 - 免疫治療における市場規模 - その他における市場規模 ・世界のキャッスルマン病治療市場規模：用途別 - 外来手術センターにおける市場規模 - 感染症における市場規模 ・世界のキャッスルマン病治療市場規模：地域別 - 南北アメリカのキャッスルマン病治療市場規模 アメリカのキャッスルマン病治療市場規模 カナダのキャッスルマン病治療市場規模 ブラジルのキャッスルマン病治療市場規模 … - アジア太平洋のキャッスルマン病治療市場規模 日本のキャッスルマン病治療市場規模 中国のキャッスルマン病治療市場規模 インドのキャッスルマン病治療市場規模 韓国のキャッスルマン病治療市場規模 台湾のキャッスルマン病治療市場規模 … - ヨーロッパ/中東/アフリカのキャッスルマン病治療市場規模 イギリスのキャッスルマン病治療市場規模 ドイツのキャッスルマン病治療市場規模 フランスのキャッスルマン病治療市場規模 ロシアのキャッスルマン病治療市場規模 … - その他地域のキャッスルマン病治療市場規模 ・競争状況 ・企業情報 |
The Global Castleman Disease Treatment Market size was estimated at USD 217.67 million in 2021 and expected to reach USD 249.01 million in 2022, and is projected to grow at a CAGR 14.57% to reach USD 492.42 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Castleman Disease Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Disease Type, the market was studied across Multicentric Castleman’s Disease and Unicentric Castleman’s Disease.
Based on Indication, the market was studied across Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor, Giant Benign Lymphoma, Giant Lymph Node Hyperplasia, and Hamartoma of the Lyphatics.
Based on Therapy, the market was studied across Antiviral Drugs, Chemotherapy, Corticosteroids, Immunotherapy, Monoclonal Antibodies, and Radiation Therapy.
Based on Application, the market was studied across Ambulatory Surgical Centers and Infectious Diseases.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Castleman Disease Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Castleman Disease Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Castleman Disease Treatment Market, including AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, EUSA Pharma, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hospira, Inc., Incyte Corporation, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Jazz Pharmaceuticals, Inc, LGM Pharma, Merck & Co., Inc., NPS Pharmaceuticals, Inc,, Octapharma AG, Pfizer, Inc., Relypsa, Inc., Sanofi S.A., Santa Cruz Biotechnology, Inc, Senhwa Biosciences, and Triveni Interchem Private Limited.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Castleman Disease Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Castleman Disease Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Castleman Disease Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Castleman Disease Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Castleman Disease Treatment Market?
6. What is the market share of the leading vendors in the Global Castleman Disease Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Castleman Disease Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Advancement in diagnosis of Castleman’s Disease demanded for further treatment options
5.1.1.2. Increasing prevalence Castleman’s Disease among AIDS patients
5.1.1.3. Government support in research and development of orphan drugs
5.1.2. Restraints
5.1.2.1. Premium pricing of drugs
5.1.2.2. Limited information about current clinical trials of the drugs
5.1.3. Opportunities
5.1.3.1. Treatment tailored to each patient’s situation
5.1.3.2. Complementary and alternative methods for treatment
5.1.4. Challenges
5.1.4.1. Limited information about causes and treatments of this rare disorder
5.2. Cumulative Impact of COVID-19
6. Castleman Disease Treatment Market, by Disease Type
6.1. Introduction
6.2. Multicentric Castleman’s Disease
6.3. Unicentric Castleman’s Disease
7. Castleman Disease Treatment Market, by Indication
7.1. Introduction
7.2. Angiofollicular Lymph Node Hyperplasia
7.3. Angiomatous Lymphoid
7.4. Castleman Tumor
7.5. Giant Benign Lymphoma
7.6. Giant Lymph Node Hyperplasia
7.7. Hamartoma of the Lyphatics
8. Castleman Disease Treatment Market, by Therapy
8.1. Introduction
8.2. Antiviral Drugs
8.3. Chemotherapy
8.4. Corticosteroids
8.5. Immunotherapy
8.6. Monoclonal Antibodies
8.7. Radiation Therapy
9. Castleman Disease Treatment Market, by Application
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Infectious Diseases
10. Americas Castleman Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Castleman Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Castleman Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Amgen Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Bayer AG
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Boehringer Ingelheim GmbH
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bristol-Myers Squibb
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. EUSA Pharma, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. F. Hoffmann-La Roche Ltd.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Gilead Sciences, Inc.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. GlaxoSmithKline PLC
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Hospira, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Incyte Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Jazz Pharmaceuticals, Inc
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. LGM Pharma
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Merck & Co., Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. NPS Pharmaceuticals, Inc,
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Octapharma AG
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Pfizer, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Relypsa, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sanofi S.A.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Santa Cruz Biotechnology, Inc
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Senhwa Biosciences
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Triveni Interchem Private Limited
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing